Skip to main content
Erschienen in:

01.02.2010 | Leitthema

„Targeted therapy“ bei metastasiertem Nierenzellkarzinom

verfasst von: Dr. M. Schenck, L.-O. Muegge

Erschienen in: Die Onkologie | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

Lange Zeit galt die Immuntherapie als mögliche Standardtherapie des fortgeschrittenen Nierenzellkarzinoms. Die Ergebnisse waren meist enttäuschend. Um die Proliferation von Tumorzellen zu blockieren, wird zunehmend versucht, gezielt in Signalkaskaden, welche die Zellproliferation regulieren, einzugreifen. Eine medikamentöse Blockade eines oder mehrerer beteiligter Signalwege mit dem Ergebnis, dass das Tumorwachstum effizient unterbunden werden kann, wurde bei der klinischen Anwendung der Multikinaseinhibitoren Sorafenib und Sunitinib gezeigt. Der zweite Signalweg, der auch bei Nierenzellkarzinomen für die Zellproliferation eine entscheidende Rolle spielt und daher ein Ziel zur Hemmung des Tumorwachstums ist, ist der PI-3-K/Akt-Signalweg. Trotz der positiven Ergebnisse muss erwähnt werden, dass eine komplette Remission durch diese beiden Substanzen sehr selten erzielt wird.
Literatur
1.
Zurück zum Zitat Motzer RJ, Mazumdar M, Bacik J et al (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928–1935PubMed Motzer RJ, Mazumdar M, Bacik J et al (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928–1935PubMed
2.
Zurück zum Zitat Atzpodien J, Kirchner H, Jonas U et al (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194CrossRefPubMed Atzpodien J, Kirchner H, Jonas U et al (2004) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194CrossRefPubMed
3.
Zurück zum Zitat Fyfe G, Fisher RI, Rosenberg SA et al (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688–696PubMed Fyfe G, Fisher RI, Rosenberg SA et al (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688–696PubMed
4.
Zurück zum Zitat Coppin C, Porzsolt F, Awa A et al (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev CD001425 Coppin C, Porzsolt F, Awa A et al (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev CD001425
5.
Zurück zum Zitat Coppin C, Porzsolt F, Kumpf J et al (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev CD001425 Coppin C, Porzsolt F, Kumpf J et al (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev CD001425
6.
Zurück zum Zitat Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310–7313PubMed Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310–7313PubMed
7.
Zurück zum Zitat Forges A de, Rey A, Klink M et al (1988) Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 4:149–154CrossRefPubMed Forges A de, Rey A, Klink M et al (1988) Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 4:149–154CrossRefPubMed
8.
Zurück zum Zitat Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540PubMed Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540PubMed
9.
Zurück zum Zitat Motzer RJ, Bacik J, Mariani T et al (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376–2381CrossRefPubMed Motzer RJ, Bacik J, Mariani T et al (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20:2376–2381CrossRefPubMed
10.
Zurück zum Zitat Motzer RJ, Hudes GR, Curti BD et al (2007) Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25:3958–3964CrossRefPubMed Motzer RJ, Hudes GR, Curti BD et al (2007) Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25:3958–3964CrossRefPubMed
11.
Zurück zum Zitat Choueiri TK, Garcia JA, Elson P et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543–550CrossRefPubMed Choueiri TK, Garcia JA, Elson P et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110:543–550CrossRefPubMed
12.
Zurück zum Zitat Furge KA, Dykema K, Petillo D et al (2007) Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Can Urol Assoc J 1:S21–S27PubMed Furge KA, Dykema K, Petillo D et al (2007) Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Can Urol Assoc J 1:S21–S27PubMed
13.
Zurück zum Zitat Hara S, Oya M, Mizuno R et al (2005) Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16:928–933CrossRefPubMed Hara S, Oya M, Mizuno R et al (2005) Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16:928–933CrossRefPubMed
14.
Zurück zum Zitat Lager DJ, Slagel DD, Palechek PL (1994) The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod Pathol 7:544–548PubMed Lager DJ, Slagel DD, Palechek PL (1994) The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod Pathol 7:544–548PubMed
15.
Zurück zum Zitat Jermann M, Stahel RA, Salzberg M et al (2006) A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57:533–539CrossRefPubMed Jermann M, Stahel RA, Salzberg M et al (2006) A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57:533–539CrossRefPubMed
16.
Zurück zum Zitat Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434CrossRefPubMed Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434CrossRefPubMed
17.
Zurück zum Zitat Escudier B, Choueiri TK, Oudard S et al (2007) Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 178:1901–1905CrossRefPubMed Escudier B, Choueiri TK, Oudard S et al (2007) Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 178:1901–1905CrossRefPubMed
18.
Zurück zum Zitat Bukowski RM, Kabbinavar FF, Figlin RA et al (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25:4536–4541CrossRefPubMed Bukowski RM, Kabbinavar FF, Figlin RA et al (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25:4536–4541CrossRefPubMed
19.
Zurück zum Zitat Hutson TE, Figlin RA (2007) Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park) 21:1175–1180; discussion 1184, 1187, 1190 Hutson TE, Figlin RA (2007) Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park) 21:1175–1180; discussion 1184, 1187, 1190
20.
Zurück zum Zitat Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428CrossRefPubMed Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428CrossRefPubMed
21.
Zurück zum Zitat Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124CrossRefPubMed Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124CrossRefPubMed
22.
Zurück zum Zitat Cella D, Li JZ, Cappelleri JC et al (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 26:3763–3769CrossRefPubMed Cella D, Li JZ, Cappelleri JC et al (2008) Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 26:3763–3769CrossRefPubMed
23.
Zurück zum Zitat Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590CrossRefPubMed Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590CrossRefPubMed
24.
Zurück zum Zitat Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10:757–763CrossRefPubMed Gore ME, Szczylik C, Porta C et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10:757–763CrossRefPubMed
25.
Zurück zum Zitat Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512CrossRefPubMed Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512CrossRefPubMed
26.
Zurück zum Zitat Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134CrossRefPubMed Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134CrossRefPubMed
27.
Zurück zum Zitat Eisen T, Oudard S, Szczylik C et al (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100:1454–1463CrossRefPubMed Eisen T, Oudard S, Szczylik C et al (2008) Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 100:1454–1463CrossRefPubMed
28.
Zurück zum Zitat Amato RJ (2007) Current immunotherapeutic strategies in renal cell carcinoma. Surg Oncol Clin N Am 16:975–986, xi–xiiCrossRefPubMed Amato RJ (2007) Current immunotherapeutic strategies in renal cell carcinoma. Surg Oncol Clin N Am 16:975–986, xi–xiiCrossRefPubMed
29.
Zurück zum Zitat Rey PM, Villavicencio H (2008) Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 74:245–246CrossRefPubMed Rey PM, Villavicencio H (2008) Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience. Oncology 74:245–246CrossRefPubMed
30.
Zurück zum Zitat Rixe O, Bukowski RM, Michaelson MD et al (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975–984CrossRefPubMed Rixe O, Bukowski RM, Michaelson MD et al (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975–984CrossRefPubMed
31.
Zurück zum Zitat Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMed Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMed
32.
Zurück zum Zitat Pouessel D, Culine S (2008) High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53:376–381CrossRefPubMed Pouessel D, Culine S (2008) High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53:376–381CrossRefPubMed
33.
Zurück zum Zitat Schrader AJ, Hofmann R (2008) Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anticancer Drugs 19:235–245CrossRefPubMed Schrader AJ, Hofmann R (2008) Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anticancer Drugs 19:235–245CrossRefPubMed
34.
Zurück zum Zitat Golshayan AR, George S, Heng DY et al (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 27:235–241CrossRefPubMed Golshayan AR, George S, Heng DY et al (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 27:235–241CrossRefPubMed
35.
Zurück zum Zitat George CM, Vogelzang NJ, Rini BI et al (2002) A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 13:116–120CrossRefPubMed George CM, Vogelzang NJ, Rini BI et al (2002) A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 13:116–120CrossRefPubMed
36.
Zurück zum Zitat Rini BI, Campbell SC (2007) The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 177:1978–1984CrossRefPubMed Rini BI, Campbell SC (2007) The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 177:1978–1984CrossRefPubMed
37.
Zurück zum Zitat Tamaskar I, Garcia JA, Elson P et al (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179:81–86; discussion 86CrossRefPubMed Tamaskar I, Garcia JA, Elson P et al (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179:81–86; discussion 86CrossRefPubMed
38.
Zurück zum Zitat Sablin MP, Negrier S, Ravaud A et al (2009) Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182:29–34; discussion 34CrossRefPubMed Sablin MP, Negrier S, Ravaud A et al (2009) Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182:29–34; discussion 34CrossRefPubMed
39.
Zurück zum Zitat Gerullis H, Bergmann L, Maute L et al (2009) Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol Gerullis H, Bergmann L, Maute L et al (2009) Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol
40.
Zurück zum Zitat Hudes G, Carducci M, Tomczak P et al (20069 A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk pathets with advanced renal cell carcinoma (advRCC). J Clin Oncol 24 (Abstr. LBA4) Hudes G, Carducci M, Tomczak P et al (20069 A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk pathets with advanced renal cell carcinoma (advRCC). J Clin Oncol 24 (Abstr. LBA4)
41.
Zurück zum Zitat Wood L, Bukowski RM, Dreicer R et al (2008) Temsiroslismus (TEM) in metastatic renal cell carcinoma (mRCC): Safetey and efficacy in patients previously treated with VEGF-targeted therapy. ASCO 2008; A353 Wood L, Bukowski RM, Dreicer R et al (2008) Temsiroslismus (TEM) in metastatic renal cell carcinoma (mRCC): Safetey and efficacy in patients previously treated with VEGF-targeted therapy. ASCO 2008; A353
42.
Zurück zum Zitat Hutson TE, Davis ID, Machiels JP et al (2007) Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 25:5031 Hutson TE, Davis ID, Machiels JP et al (2007) Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol 25:5031
43.
Zurück zum Zitat Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Bukowski RM, Scheuring UJ, Burk K, Escudier B (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 25:5025 Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Bukowski RM, Scheuring UJ, Burk K, Escudier B (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 25:5025
44.
Zurück zum Zitat Shepard DR, Rini BI, Garcia JA et al (2008) A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 26:5123 Shepard DR, Rini BI, Garcia JA et al (2008) A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 26:5123
Metadaten
Titel
„Targeted therapy“ bei metastasiertem Nierenzellkarzinom
verfasst von
Dr. M. Schenck
L.-O. Muegge
Publikationsdatum
01.02.2010
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 2/2010
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-009-1760-7

Weitere Artikel der Ausgabe 2/2010

Der Onkologe 2/2010 Zur Ausgabe

CME Weiterbildung · Zertifizierte Fortbildung

Sport bei Krebspatienten

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.